Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002;53 Suppl 1(Suppl 1):45S-52S.
doi: 10.1046/j.0306-5251.2001.00032.x.

A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction

Affiliations
Clinical Trial

A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction

Peter A Milligan et al. Br J Clin Pharmacol. 2002.

Abstract

Aims: To analyse the pharmacokinetics of sildenafil citrate in patients with erectile dysfunction in order to characterize covariate relationships and assist in the development of rational dosage strategies.

Methods: A population pharmacokinetic sampling strategy was incorporated into five phase III clinical study protocols. Overall, 2077 patients, 1335 of whom received sildenafil, were asked to take an additional dose of study drug before their scheduled clinic visits on four or five occasions throughout the study duration. A single plasma sample was obtained at random times postdose (range 1--7 h), and a total of 4582 samples were assayed (average 3.4 samples per individual).

Results: For the population average patient (age 58 years; aspartate transaminase [AST], 24 IU l(-1); weight, 87 kg; not receiving CYP3A4 potential inhibitors), typical values for sildenafil (mean +/- SE) were 58.5 +/- 1.4 l h(-1) for apparent clearance (CL/F), 310 +/- 6.92 l for volume of distribution (V/F), and 2.6 +/- 0.176 h(-1) for first-order absorption constant (ka). The value for ka is associated with meal consumption within 2 h predose, at all other times ka was equivalent to an instantaneous bolus administration. The interindividual variabilities were 29% for CL/F, 20% for V/F, and 210% for ka. Over a dose range of 25--100 mg sildenafil, the pharmacokinetics exhibited dose proportionality. There was evidence of nonproportionality (40% increase on average) in relative bioavailability with respect to the 200-mg dose (P<0.001) relative to the other doses. Age, AST concentration, and co-administration with CYP3A4 potential inhibitors significantly influenced CL/F of sildenafil (P<0.001, for each relationship). For age and AST, the extent of the linear relationships (extrapolated from population average values) included a 4% decrease in CL/F for every decade increase and a 6% decrease in CL/F for every 10-unit increase, respectively. Following co-administration of CYP3A4 potential inhibitors, a 14% decrease in CL/F was estimated. Only body weight was found to significantly (P<0.001) influence V/F (a 6% increase in V/F for every 10-kg increase).

Conclusions: The pharmacokinetics of, and covariate influences on, sildenafil in patients with erectile dysfunction were shown to be consistent with those demonstrated in phase I volunteer studies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sildenafil Concentration vs time after dose.
Figure 2
Figure 2
Observed (DV) vs model-predicted sildenafil plasma concentrations. The left-hand panel shows the population-predicted (PRED) and the right-hand panel the individually predicted (IPRE) sildenafil plasma concentrations.

Similar articles

Cited by

References

    1. Feldman HA, Goldstein I, Hatzichristou D, Krane R, McKinlay J. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61. - PubMed
    1. Linet O, Ogrine F. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Eng J Med. 1996;334:873–877. - PubMed
    1. Aloni R, Heller L, Keren O, Mendelson E, Davidoff G. Noninvasive treatment for erectile dysfunction in the neurogenically disabled population. J Sex Marital Ther. 1992;18:243–249. - PubMed
    1. Padma-Nathan H, Hellstrom W, Kaiser F. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997;336:1–7. - PubMed
    1. Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397–1404. - PubMed

Publication types

MeSH terms

LinkOut - more resources